1.
Antimicrob Agents Chemother
; 48(2): 635-7, 2004 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-14742225
RESUMO
The pharmacokinetics of 2,000 mg of sulfadiazine administered twice daily (BID) versus those of 1,000 mg administered four times a day were compared in eight human immunodeficiency virus-infected patients. No differences in pharmacokinetic parameters were detected between the regimens. These data provide a pharmacokinetic rationale for BID dosing of sulfadiazine for the treatment and suppression of toxoplasmosis.